Ovid Therapeutics Inc. (OVID)

Market Cap	381.12M +1,680.9%
Revenue (ttm)	7.25M +1,181.3%
Net Income	-17.14M
EPS	-0.23
Shares Out	131.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,394
Open	n/a
Previous Close	2.850
Day's Range	n/a
52-Week Range	0.265 - 3.105
Beta	-0.03
Analysts	Strong Buy
Price Target	4.60 (+59.17%)
Earnings Date	May 12, 2026

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's d...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 5, 2017
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: OVID
• Website: https://www.ovidrx.com

Financial Performance

In 2025, Ovid Therapeutics's revenue was $7.25 million, an increase of 1181.27% compared to the previous year's $566,000. Losses were -$17.14 million, -34.01% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price target is $4.6, which is an increase of 59.17% from the latest price.

Price Target

$4.6

(59.17% upside)

Analyst Consensus: Strong Buy